Insider Buying This Week: A Three-Day Streak, a Director's Small Add, and a Fund Building a Stake
Sourced from public SEC EDGAR filings. Informational only — not investment advice, and not a recommendation to buy, sell, or hold any security.
Three Form 4 filings from this week illustrate three different shapes open-market insider buying can take — a multi-day executive buying streak, a small routine director purchase, and a large institutional stake build. All figures below are taken directly from the filings.
Navios Maritime Partners (NMM): three consecutive buying days
Angeliki Frangou, listed on the filing as both a director and officer of Navios Maritime Partners L.P. (ticker NMM), reported open-market purchases on three consecutive trading days:
| Date | Shares | Price/share |
|---|---|---|
| 2026-08-05 | 1,064 | $78.4133 |
| 2026-08-06 | 1,063 | $79.5271 |
| 2026-08-07 | 1,054 | $78.9380 |
Roughly 3,181 shares acquired across the three days at an average price just under $79. Consecutive-day open-market buying by the same insider, rather than a single lump purchase, often reflects a standing 10b5-1 purchase plan rather than a one-off decision — the filing itself doesn’t say either way, so that’s noted here as a general pattern, not a claim about this specific plan.
Landmark Bancorp (LARK): a director tops up
Mark J. Kohlrus, a director of Landmark Bancorp, filed two smaller purchases:
| Date | Shares | Price/share |
|---|---|---|
| 2026-08-06 | 201 | $31.50 |
| 2026-08-07 | 799 | $31.8344 |
1,000 shares total, worth a little over $31,700 combined at the filed prices — a modest add relative to the Navios purchases above, and a good reminder that “insider buying” covers everything from routine small top-ups to large institutional moves.
Attovia Therapeutics (ATTO): a fund builds a position
Not every Form 4 purchase comes from a company officer or director. Redmile Group, LLC — an investment manager, filing as a greater-than-10% beneficial owner rather than as an officer or director — reported two same-day purchases in Attovia Therapeutics:
| Date | Shares | Price/share |
|---|---|---|
| 2026-08-06 | 200,000 | $17.00 |
| 2026-08-06 | 400,000 | $17.00 |
600,000 shares at $17.00 flat, roughly $10.2 million at the filed price. Worth flagging the distinction: this is a fund’s beneficial-ownership filing, not an executive putting personal money into the company they run — a meaningfully different signal than the Navios and Landmark Bancorp purchases above, even though all three show up under the same “Form 4” label.
All transaction data pulled directly from Form 4 filings on SEC EDGAR. Not investment advice — see About for what this site does and doesn’t do.